Accelerated 30 minutes-infusion ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01346826 (ClinicalTrials.gov)	May 2011	2/5/2011	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial	Crohn's Disease;Ulcerative Colitis	Drug: Standard 2 hours-infusion;Drug: Accelerated 1 hour-infusion;Drug: Accelerated 30 minutes-infusion	Asan Medical Center	NULL	Completed	16 Years	80 Years	Both	145	Phase 4	Korea, Republic of

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01346826 (ClinicalTrials.gov)	May 2011	2/5/2011	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)	Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial	Crohn's Disease;Ulcerative Colitis	Drug: Standard 2 hours-infusion;Drug: Accelerated 1 hour-infusion;Drug: Accelerated 30 minutes-infusion	Asan Medical Center	NULL	Completed	16 Years	80 Years	Both	145	Phase 4	Korea, Republic of